Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 3/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22277155 | 1.00 | MEN1 (0.50) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL5089242 | 1.00 | MEN1 (0.50) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| Hydrochloric Acid SCHEMBL6241672 | 0.98 | MEN1 (0.48) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL19145361 | 0.98 | MEN1 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7935092 | 0.91 | MEN1 (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL434308 | 0.86 | MEN1 (0.48) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL7439215 | 0.85 | NPY4R (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL433663 | 0.84 | MEN1 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL17525175 | 0.83 | MEN1 (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL11418945 | 0.83 | MEN1 (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| EP-2410842-B1 | SANITIZER FORMULATIONS | ARCH CHEM INC (US) | 2017-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | RNMT, RNGTT, CAPG | MEN1 3586/4885CYP1A2 4135/4885KMT2A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.